# GLP-1 Indications Continue to Expand: Potential approvals expected through 2026 | Lockton

Zdroj: [https://global.lockton.com/us/en/news-insights/glp-1-indications-continue-to-expand-potential-approvals](https://global.lockton.com/us/en/news-insights/glp-1-indications-continue-to-expand-potential-approvals)

ARTICLES / AUGUST 26, 2025
Following other expanded indications (opens a new window) for GLP-1s, Wegovy has now received FDA approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis. This marks a significant expansion in the therapeutic landscape for GLP-1s, highlighting their growing role in addressing complex metabolic conditions. The growing GLP-1 approval pipeline has significant implications for employers in terms of cost, coverage, and employee access.
